文献速递哮喘

轻度-中度哮喘患者选择治疗时最看重什么?离散选择实验的结果

What matters most to patients when choosing treatment for mild-moderate asthma? Results from a discrete choice experiment.
PubMed 文献 · Thorax · 2020-07-27

该研究是在PRACTICAL试验中开展的一项子组分析,纳入288例轻度哮喘成人患者,采用离散选择实验(1000minds软件,PAPRIKA方法)评估治疗属性相对重要性。64%的参与者偏好按需联合预防-缓解治疗;无气短和最低哮喘急性发作风险分别排名第一和第二,治疗方案属性的相对重要性因偏好治疗而异。

要点

  • 轻度哮喘患者最看重无气短和最低急性发作风险。
  • 64%的参与者偏好按需联合预防-缓解治疗。
  • 治疗方案的相对重要性因患者偏好治疗而异。

核心结论

  • 了解患者对治疗属性的偏好及方案特征可用于轻度-中度哮喘治疗选择的共享决策。

研究设计与样本

  • 在PRACTICAL随机对照试验的子组分析中,参与者在最终访视时完成离散选择实验(PAPRIKA方法,1000minds软件)。
  • 最终分析数据集包括288例参与者。

主要发现

  • 64%的参与者偏好按需联合预防-缓解治疗。
  • 无气短排名最高,最低哮喘急性发作风险排名第二。
  • 治疗方案属性的相对重要性因偏好治疗而异:偏好按需治疗的参与者比偏好维持治疗的参与者更看重治疗方案。

临床怎么用

  • 可将患者对治疗属性的偏好与方案特征结合,用于轻度-中度哮喘的共享决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An as-needed combination preventer and reliever regimen was recently introduced as an alternative to conventional daily preventer treatment for mild asthma. In a subgroup analysis of the PRACTICAL study, a pragmatic randomised controlled trial of budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild asthma, we recently reported that about two-thirds preferred as-needed combination preventer and reliever therapy. The aim of this study was to determine the relative importance of attributes associated with these two asthma therapies in this subgroup of participants who indicated their preferred treatment in the PRACTICAL study. METHODS: At their final study visit, a subgroup of participants indicated their preferred treatment and completed a discrete choice experiment using the Potentially All Pairwise RanKings of all possible Alternatives method and 1000minds software. Treatment attributes and their levels were selected from measurable study outcomes, and included: treatment regimen, shortness of breath, steroid dose and likelihood of asthma flare-up. RESULTS: The final analysis dataset included 288 participants, 64% of whom preferred as-needed combination preventer and reliever. Of the attributes, no shortness of breath and lowest risk of asthma flare-up were ranked highest and second highest, respectively. However, the relative importance of the other two attributes varied by preferred therapy: treatment regimen was ranked higher by participants who preferred as-needed treatment than by participants who preferred maintenance treatment. CONCLUSIONS: Knowledge of patient preferences for treatment attributes together with regimen characteristics can be used in shared decision-making regarding choice of treatment for patients with mild-moderate asthma. TRIAL REGISTRATION NUMBER: ACTRN12616000377437.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Baggott C, Hansen P, Hancox RJ, et al. What matters most to patients when choosing treatment for mild-moderate asthma? Results from a discrete choice experiment. Thorax. 2020. PMID: 32719055. doi:10.1136/thoraxjnl-2019-214343

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。